Pharmaceutical Benefits Scheme: Takhzyro approved for hereditary angioedema ...
Reprieve for Australians who suffer rare and deadly genetic condition as a $241,000-a-year medicine is listed on the pharmaceutical benefits scheme Expensive angioedema medicine to be listed on Australian government scheme Pharmaceutical Benefits Scheme slashes the price of important medicines Patients will now pay $41.30 per script rather than $241,000, Greg Hunt says
View
comments
